In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing large ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor.
This project is funded by the European Union’s EIC-Pathfinder Programme, under the Grant Agreement number 101130454
ISOS presents a visionary approach to in situ fabrication and auto-renewed delivery of therapeutic compounds.
ISOS aims to seamlessly integrate genetically engineered bacteria into a biomaterial-based bioreactor.
ISOS targets the wet form of age-related macular degeneration, proposing a genetically engineered bacteria bioreactor to replace frequent injections against vascular endothelial growth factor.
This initiative holds the promise of transforming prolonged treatments into personalised, efficient and minimally invasive healthcare experiences.
On February 6, 2025, we were thrilled to see several pioneering projects from the EIC ELMs Portfolio — PRISM-LT, -LoopOfFun-ELMs, NextSkins, Bio-HhOST, BioRobot-MiniHeart, ISOS Project EU, Bioaction EU, REMEDY — participate in the EIC-EMA Workshop on the Regulatory Framework of Engineered Living Materials (ELMs).
Discover why the European Innovation Council (EIC) is prioritizing portfolio management to boost Europe’s technological autonomy. Learn which are the projects in the portfolio working on common research interests and challenges to increase the chances of success.
Discover how each project in the EIC ELMs portfolio aims to develop cheaper and more sustainable materials, using living materials in a new video by Horizon Results Booster.
Discover the objectives and the activities to reach those objectives of the EIC ELMs Portfolio in advancing living materials technology and shaping Europe’s leadership in this field. This strategic plan is a living document. Future updates can be found in the yearly progress reports of the EIC ELMs Portfolio.
